MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lipid metabolism"

  • 2025 International Congress

    Efficacy of adhering to a Ketogenic Diet in Parkinson’s Disease: a Systematic Review and Meta-Analysis

    G. Guindani Maia, V. Ritt Xavier, V. Serafim, M. Neto, L. Nardi Motta, V. Müller, I. Alicia Fink, AC. Sgarioni Viapiana, MF. Peruci Felippe, L. Bedatti Koehler, C. Rieder (Porto Alegre, Brazil)

    Objective: We aimed to analyse the efficacy of Ketogenic Diet (KD) in metabolic and motor characteristics of patients with Parkinson's Disease (PD). Background: Many studies…
  • 2025 International Congress

    Cerebrospinal fluid measured α-synuclein is related to metabolite profile in the serum and CSF

    K. Paul, D. Jones, B. Ritz (Los Angeles, USA)

    Objective: Determine metabolites associated with cerebrospinal fluid (CSF) measured α-synuclein (α-syn) using untargeted metabolomics measured in the serum and CSF. Background: Several large studies have…
  • 2025 International Congress

    The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To assess the effects of statin therapy on motor and non-motor symptoms in Parkinson’s disease (PD) through a meta-analysis of randomized controlled trials. Background:…
  • 2025 International Congress

    The sphingolipid Lyso-Gb3, a biomarker for the lysosomal storage disorder Fabry Disease, is significantly elevated in blood from patients with Parkinson’s Disease

    C. Beetz, C. Cozma, M. Iurascu, S. Fischer, S. Oppermann, K. Kandaswamy, P. Bauer (Rostock, Germany)

    Objective: To better understand lysosomal dysfunction in Parkinson’s Disease. Background: Lysosomal dysfunction and α-synuclein accumulation play central roles in Parkinson’s Disease. They are interconnected by…
  • 2025 International Congress

    Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics

    J. Suh, R. Maciuca, E. Macklin, S. Davis, J. Kluss, N. Xia, H. Yazd, M. Schwarzschild, S. Huntwork-Rodriguez (South San Francisco, USA)

    Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…
  • 2025 International Congress

    The Impact of Anodal transcranial Direct Current Stimulation on the Metabolomic Profiles of Cerebrospinal Fluid in Parkinson’s Disease

    KW. Park, WY. Jang, KS. Jang, MR. Choi (Gangneung-si, Republic of Korea)

    Objective: To explore the impact of anodal transcranial direct current stimulation (tDCS) on the cerebrospinal fluid (CSF) metabolomic profile of Parkinson's disease (PD). Background: Transcranial…
  • 2025 International Congress

    Platelets Lipidome as Potential Biomarker of Parkinson’s Disease

    G. Uras, S. Lucas-Del-Pozo, V. Lentini, F. Fierli, S. Koletsi, D. Hughes, A. Schapira, . (London, United Kingdom)

    Objective: The aim of this proejct is to identify novel biomarkers of Parkinson's disease diagnosis and progression, with a focus on GBA-PD. Background: Our previous…
  • 2025 International Congress

    Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases

    S. Abdelaziz, A. Helmy, E. Hamid, M. Salama, A. Shalash (Cairo, Egypt)

    Objective: To identify differential serum metabolites found in AD and PD patients and their correlations to clinical presentation in Egyptian patients. Background: There is a…
  • 2025 International Congress

    Plasma Lipids as Potential Biomarkers for Progression of Sleep Disturbances in Parkinson’s Disease

    M. Mchorney, R. Rajhmohan, J. Ruiz Tejeda, N. Phielipp (Irvine, USA)

    Objective: Determine if plasma lipid levels can serve as a surrogate biomarker of future onset of RBD symptoms or nighttime sleep burden in patients with…
  • 2025 International Congress

    Sex specific role of dyslipidemia and statin use in Parkinson’s disease pathogenesis

    K. Tsutsumi, E. Shah, S. Isfahani (Orange, USA)

    Objective: Our aim was to characterize the role of dyslipidemia and statin use in Parkinson’s disease (PD) development, specifically with respect to differences in significance…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley